

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)  
Approved for use through 07/31/96, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO Rev. 10/95		U.S. Department of Commerce Patent and Trademark Office		<b>Complete if Known</b>	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/524,060
				Filing Date	February 8, 2005
				First Named Inventor	Zhiming SUO, M.D., Ph.D.
				Group Art Unit	1649
				Examiner Name	WANG, Chang Yu
Sheet	1	of	6	Attorney Docket Number	US 1421/05 (VA)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
Cyw		Braak, H. & Braak, E. Neuropathological staging of Alzheimer-related changes. <i>Acta Neuropathol (Berl)</i> 82, 239-59 (1991).	
		Saitoh, T., Horsburgh, K. & Masliah, E. Hyperactivation of signal transduction systems in Alzheimer's disease. <i>Ann N Y Acad Sci</i> 695, 34-41 (1993).	
		Fowler, C.J., Cowburn, R.F., Garlind, A., Winblad, B. & O'Neill, C. Disturbances in signal transduction mechanisms in Alzheimer's disease. <i>Mol Cell Biochem</i> 149-150, 287-92 (1995).	
		Joseph, J.A., Cutler, R. & Roth, G.S. Changes in G protein-mediated signal transduction in aging and Alzheimer's disease. <i>Ann N Y Acad Sci</i> 695, 42-5 (1993).	
		Shimohama, S. et al. Aberrant phosphoinositide metabolism in Alzheimer's disease. <i>Ann N Y Acad Sci</i> 695, 46-9 (1993).	
		Matsushima, H., Shimohama, S., Chachin, M., Taniguchi, T. & Kimura, J. Ca <sup>2+</sup> -dependent and Ca <sup>2+</sup> -independent protein kinase C changes in the brain of patients with Alzheimer's disease. <i>J Neurochem</i> 67, 317-23 (1996).	
		Mattson, M.P. & Chan, S.L. Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. <i>J Mol Neurosci</i> 17, 205-24 (2001).	
		Fowler, C.J., Garlind, A., O'Neill, C. & Cowburn, R.F. Receptor-effector coupling dysfunctions in Alzheimer's disease. <i>Ann N Y Acad Sci</i> 786, 294-304 (1996).	
		Hisatomi, O. et al. A novel subtype of G-protein-coupled receptor kinase, GRK7, in teleost cone photoreceptors. <i>FEBS Lett</i> 424, 159-64. (1998).	
Cyw		Pitcher, J.A., Freedman, N.J. & Lefkowitz, R.J. G protein-coupled receptor kinases. <i>Annu Rev Biochem</i> 67, 653-92 (1998).	

Examiner Signature	<i>Chang Yu Wang</i>	Date Considered	10/27/05
--------------------	----------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)  
Approved for use through 07/31/96, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO Rev. 10/95		U.S. Department of Commerce Patent and Trademark Office		<b>Complete if Known</b>	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/524,060
				Filing Date	February 8, 2005
				First Named Inventor	Zhiming SUO, M.D., Ph.D.
				Group Art Unit	1649
				Examiner Name	WANG, Chang Yu
Sheet	2	of	6	Attorney Docket Number	US 1421/05 (VA)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
Cyw		Sallese, M. et al. Regulation of G protein-coupled receptor kinase subtypes by calcium sensor proteins. <i>Biochim Biophys Acta</i> 1498, 112-21. (2000).	
		Bristow, M.R. et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. <i>Circulation</i> 82, 112-25 (1990).	
		Ungerer, M., Kessebohm, K., Kronsbein, K., Lohse, M.J. & Richardt, G. Activation of beta-adrenergic receptor kinase during myocardial ischemia. <i>Circ Res</i> 79, 455-60 (1996).	
		Gros, R., Benovic, J.L., Tan, C.M. & Feldman, R.D. G-protein-coupled receptor kinase activity is increased in hypertension. <i>J Clin Invest</i> 99, 2087-93 (1997).	
		Premont, R.T., Inglese, J. & Lefkowitz, R.J. Protein kinases that phosphorylate activated G protein-coupled receptors. <i>Faseb J</i> 9, 175-82 (1995).	
		Chen, J., Makino, C.L., Peachey, N.S., Baylor, D.A. & Simon, M.I. Mechanisms of rhodopsin inactivation in vivo as revealed by a COOH-terminal truncation mutant. <i>Science</i> 267, 374-7 (1995).	
		Terwilliger, R.Z., Ortiz, J., Guitart, X. & Nestler, E.J. Chronic morphine administration increases beta-adrenergic receptor kinase (beta ARK) levels in the rat locus coeruleus. <i>J Neurochem</i> 63, 1983-6 (1994).	
		Barak, L.S., Warabi, K., Feng, X., Caron, M.G. & Kwatra, M.M. Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and beta-arrestin 2 during homologous desensitization of the substance P receptor. <i>J Biol Chem</i> 274, 7565-9 (1999).	
		Harlan, J.E., Hajduk, P.J., Yoon, H.S. & Fesik, S.W. Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate. <i>Nature</i> 371, 168-70 (1994).	
Cyw		DebBurman, S.K., Ptasienski, J., Benovic, J.L. & Hosey, M.M. G protein-coupled receptor kinase GRK2 is a phospholipid-dependent enzyme that can be conditionally activated by G protein betagamma subunits. <i>J Biol Chem</i> 271, 22552-62 (1996).	

Examiner Signature		Date Considered	10/27/05
--------------------	---	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08B (6-95)  
Approved for use through 07/31/96, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO  
Rev. 10/95

U.S. Department of Commerce  
Patent and Trademark Office

# LIST OF PRIOR ART CITED BY APPLICANT

(use as many sheets as necessary)



## Complete if Known

Application Number	10/524,060
Filing Date	February 8, 2005
First Named Inventor	Zhiming SUO, M.D., Ph.D.
Group Art Unit	1649
Examiner Name	WANG, Chang Yu
Attorney Docket Number	US 1421/05 (VA)

Sheet 3 of 6

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc., date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
CYW		Freeman, J.L., Pitcher, J.A., Li, X., Bennett, V. & Lefkowitz, R.J. alpha-Actinin is a potent regulator of G protein-coupled receptor kinase activity and substrate specificity in vitro. <i>FEBS Lett</i> 473, 280-4 (2000).	
		Roth, G.S., Joseph, J.A. & Mason, R.P. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. <i>Trends Neurosci</i> 18, 203-6 (1995).	
		Price, D.L. et al. Sequestration of tubulin in neurons in Alzheimer's disease. <i>Brain Res</i> 385, 305-10 (1986).	
		Wallace, M.A. Effects of Alzheimer's disease-related beta amyloid protein fragments on enzymes metabolizing phosphoinositides in brain. <i>Biochim Biophys Acta</i> 1227, 183-7 (1994).	
		Mattson, M.P. et al. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. <i>J Neurosci</i> 12, 376-89 (1992).	
		Chishti, M.A. et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of APP695. <i>J Biol Chem</i> 276(24):21562-70 (2001).	
		Schutzer, W.E., Reed, J.F., Blizotes, M. & Mader, S.L. Upregulation of G protein-linked receptor kinases with advancing age in rat aorta. <i>Am J Physiol Regul Integr Comp Physiol</i> 280, R897-903 (2001).	
		Griffin, W.S. et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. <i>Brain Pathol</i> 8, 65-72 (1998).	
		Suo, Z. et al. Participation of protease-activated receptor-1 in thrombin-induced microglial activation. <i>J Neurochem</i> 80, 655-66 (2002).	
CYW		Crawford, F. et al. Alzheimer's beta-amyloid vasoactivity: identification of a novel beta- amyloid conformational intermediate. <i>FEBS Lett</i> 436, 445-8 (1998).	

Examiner  
Signature

*Chang Yu Wang*

Date  
Considered

10/27/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)  
Approved for use through 07/31/96, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO Rev. 10/95		U.S. Department of Commerce Patent and Trademark Office		<b>Complete if Known</b>	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/524,060
				Filing Date	February 8, 2005
				First Named Inventor	Zhiming SUO, M.D., Ph.D.
				Group Art Unit	1649
				Examiner Name	WANG, Chang Yu
Sheet	4	of	6	Attorney Docket Number	US 1421/05 (VA)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
CYW		Tiruppathi, C. et al. G protein-coupled receptor kinase-5 regulates thrombin-activated signaling in endothelial cells. <i>Proc Natl Acad Sci U S A</i> 97, 7440-5 (2000).	
		Shapiro, M.J., Weiss, E.J., Faruqi, T.R. & Coughlin, S.R. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. <i>J Biol Chem</i> 275, 25216-21. (2000).	
		Noda, M., Nakanishi, H., Nabekura, J. & Akaike, N. AMPA-kainate subtypes of glutamate receptor in rat cerebral microglia. <i>J Neurosci</i> 20, 251-8 (2000).	
		Hajjar, A.M., Ernst, R.K., Tsai, J.H., Wilson, C.B. & Miller, S.I. Human Toll-like receptor 4 recognizes host-specific LPS modifications. <i>Nat Immunol</i> 3, 354-9 (2002).	
		Stanciu, M. et al. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. <i>J Biol Chem</i> 275, 12200-6 (2000).	
		Iversen, L.L., Mortishire-Smith, R.J., Pollack, S.J. & Shearman, M.S. The toxicity in vitro of beta-amyloid protein. <i>Biochem J</i> 311, 1-16 (1995).	
		Meda, L. et al. Activation of microglial cells by beta-amyloid protein and interferon- gamma. <i>Nature</i> 374, 647-50 (1995).	
		Lue, L.F. et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. <i>Am J Pathol</i> 155(3):853-62 (1999).	
		Sigurdsson, E.M., Scholtzova, H., Mehta, P.D., Frangione, B. & Wisniewski, T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. <i>Am J Pathol</i> 159, 439-47. (2001).	
CYW		Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. <i>Science</i> 293, 1487-91 (2001).	

Examiner Signature	<i>Chang Yu Wang</i>	Date Considered	10/27/05
--------------------	----------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)  
Approved for use through 07/31/96, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO Rev. 10/95		U.S. Department of Commerce Patent and Trademark Office		<b>Complete if Known</b>	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/524,060
				Filing Date	February 8, 2005
				First Named Inventor	Zhiming SUO, M.D., Ph.D.
				Group Art Unit	1649
				Examiner Name	WANG, Chang Yu
Sheet	5	of	6	Attorney Docket Number	US 1421/05 (VA)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
Cyw		Sandhu, F.A. et al. NMDA and AMPA receptors in transgenic mice expressing human beta- amyloid protein. <i>J Neurochem</i> 61, 2286-9. (1993).	
		Smith, D.H. et al. Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. <i>Am J Pathol</i> 153, 1005-10 (1998).	
		Aragay, A.M. et al. Monocyte chemoattractant protein-1-induced CCR2B receptor desensitization mediated by the G protein-coupled receptor kinase 2. <i>Proc Natl Acad Sci U S A</i> 95, 2985-90 (1998).	
		Crawford, F., Suo, Z., Fang, C. & Mullan, M. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. <i>Exp Neurol</i> 150, 159-68 (1998).	
		Suo, Z. et al. Soluble Alzheimers beta-amyloid constricts the cerebral vasculature in vivo. <i>Neurosci Lett</i> 257, 77-80 (1998).	
		Federal Interagency Forum on Aging-Related Statistics. 2000. Older Americans 2000: Key Indicators of Well-Being. Web site: <a href="http://www.agingstats.gov/chartbook2000/population.html">http://www.agingstats.gov/chartbook2000/population.html</a> . (January 14, 2002.)	
		FMG Innovations dba Alzheimer's Test Kit. 2001. Early Alert Alzheimer's Home Screening Test. April 23, 2001. Web site: <a href="http://www.alzheimerstestkit.com/">http://www.alzheimerstestkit.com/</a> (October 8, 2001.)	
		Fraser P. E., G. Yu, L. Levesque, M. Nishimura, D. S. Yang, H. T. J. Mount, D. Westaway, and P. H. St-George-Hyslop. February 2001. Presenilin function: connections to Alzheimer's disease and signal transduction. <i>Biochemical Society Symposia</i> 67:89-100.	
		Freeman J. L., E. M. De La Cruz, T. D. Pollard, R. J. Lefkowitz, and J. A. Pitcher. August 7, 1998. Regulation of G protein-coupled receptor kinase 5 (GRK5) by actin. <i>Journal of Biological Chemistry</i> 273(32):20653-20657.	
Cyw		Market News Publishing Inc. 2001. Nycomed Amersham Imaging and Neurochem collaborate to create Alzheimer's diagnostic. <i>Intelihealth Inc.</i> July 19, 2001. Web site: <a href="http://ipn.intelihealth.com/IPN/ihIPN/WSIPN000/23883/7194/328776.html">http://ipn.intelihealth.com/IPN/ihIPN/WSIPN000/23883/7194/328776.html</a> . (October 8, 2001.)	

Examiner Signature	<i>Chang-Yu Wang</i>	Date Considered	10/27/05
--------------------	----------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)  
Approved for use through 07/31/96, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO Rev. 10/95		U.S. Department of Commerce Patent and Trademark Office		<b>Complete if Known</b> Application Number <b>10/524,060</b> Filing Date <b>February 8, 2005</b> First Named Inventor <b>Zhiming SUO, M.D., Ph.D.</b> Group Art Unit <b>1649</b> Examiner Name <b>WANG, Chang Yu</b> Attorney Docket Number <b>US 1421/05 (VA)</b>	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (use as many sheets as necessary)					
Sheet	6	of	6		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
CYW		McLean C. A., R. A. Cherny, F. W. Fraser, S. J. Fuller, M. J. Smith, K. Beyreuther, Al Bush, and C. L. Masters. December 1999. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. <i>Annals of Neurology</i> 46:860-866.	
		Medical DeviceLink. 1997. Test developers pursue early Alzheimer's disease diagnostic. <i>IVD Technology Magazine</i> . March 1997. Web site: <a href="http://www.devicelink.com/ivdt/archive/97/03/003.html">http://www.devicelink.com/ivdt/archive/97/03/003.html</a> . (October 8, 2001.)	
		National Institute on Aging. 2001. <i>Alzheimer's Disease Fact Sheet</i> . Alzheimer's Disease Education & Referral Center, National Institute on Aging, National Institutes of Health. 2001. Web site: <a href="http://www.alzheimers.org/pubs/adfact.html">http://www.alzheimers.org/pubs/adfact.html</a> (December 5, 2002.)	
		National Institutes of Health. 1994. <i>Alzheimer's Disease</i> . Web site: <a href="http://www.pueblo.gsa.gov/cic_text/health/alzheim/alzheim.htm">http://www.pueblo.gsa.gov/cic_text/health/alzheim/alzheim.htm</a> . (October 8, 2001.)	
		Neve R. L., D. L. McPhie, and Y. Chen. February 2001. Alzheimer's disease: dysfunction of a signalling pathway mediated by the amyloid precursor protein? <i>Biochemical Society Symposia</i> 67:37-50.	
		O'Neill C., R. F. Cowburn, W. L. Bonkale, T. G. Ohm, J. Fastborn, M. Carmody, and M. Kelliher. February 2001. Dysfunctional intracellular calcium homeostasis: a central cause of neurodegeneration in Alzheimer's disease. <i>Biochemical Society Symposia</i> 67:177-194.	
		Pitcher J. A., R. A. Hall, Y. Daaka, J. Zhang, S. S.G. Ferguson, S. Hester, S. Miller, M. G. Caron, R. J. Lefkowitz, and L. S. Barak. May 15, 1998. The G protein-coupled receptor kinase 2 is a microtubule-associated protein kinase that phosphorylates tubulin. <i>Journal of Biological Chemistry</i> 273(20):12316-12324.	
		Silva, Chris. 2001. Joining the great chase: Rockville biotech firm is among those racing to find an Alzheimer's cure. <i>Washington Business Journal</i> . May 25, 2001. Web site: <a href="http://washington.bcentral.com/washington/stories/2001/05/28/focus1.html">http://washington.bcentral.com/washington/stories/2001/05/28/focus1.html</a> . (October 8, 2001.)	
		Strittmatter W. J. February 2001. Apolipoprotein E and Alzheimer's disease: signal transduction mechanisms. <i>Biochemical Society Symposia</i> 67:101-109.	
CYW		Suo Z., M. Wu, S. Ameenuddin, H. E. Anderson, J. E. Zoloty, B. A. Citron, P. Andrade-Gordon, and B. W. Festoff. February 2002. Participation of protease-activated receptor-1 in thrombin-induced microglial activation. <i>Journal of Neurochemistry</i> 80(4):655-666.	

Examiner Signature	<i>Chang Yu Wang</i>	Date Considered	10/27/05
--------------------	----------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



~~DTIC~~ DTIC PCT/  
Compl Known

~~00 FEB 2005~~

U.S. Department of Commerce  
Patent and Trademark Office

**(use as many sheets as necessary)**

1

of

2

**N/A**

**Herewith**

**Zhiming SUO, M.D., Ph.D.**

1

[illegible]

**US 1421/05 (VA)**

[illegible][illegible]

Chang-Yung

10/27/05

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1 <sup>6</sup> if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (6-95)  
Approved for use through 07/31/96, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO  
Rev. 10/95

U.S. Department of Commerce  
Patent and Trademark Office

Comp. If Known

# LIST OF PRIOR ART CITED BY APPLICANT

(use as many sheets as necessary)

Application Number N/A 10/524060  
Filing Date Herewith  
First Named Inventor Zhiming SUO, M.D., Ph.D.  
Group Art Unit  
Examiner Name  
Attorney Docket Number US 1421/05 (VA)

Sheet

2

of

2

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T <sup>2</sup>
Cyw		COWBURN et al., Receptor-G-protein signalling in Alzheimer's disease. Biochem. Soc. Symp., 2001, Vol 67, pp.167-175.	
		PENN et al., Regulation of G-protein coupled receptor kinases. Trends Cardiovascul. Med., 2000, Vol. 10, No. 2, pp. 81-89.	
Cyw		MURPHY et al., Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunochemical reactivity in Alzheimer's disease and related disorders. American J. Pathology, 1994, Vol. 144, No. 5, pp. 1082-88.	

Examiner  
Signature

Chang Sun

Date  
Considered

10/27/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.